Semaglutide Investigated for Weight Loss, Body Composition in Elderly Obese Patients

<b>Obesity</b> in elderly patients presents unique challenges, often exacerbating comorbidities like cardiovascular disease and metabolic dysfunction, while significantly reducing quality of life and functional independence. Standard weight loss interventions, combining personalized lifestyle and exercise, may have limited efficacy or adherence in this demographic due to age-related physiological changes, sarcopenia risk, and existing health conditions. <b>Semaglutide</b>, a GLP-1 receptor agonist, has demonstrated substantial weight loss and cardiometabolic benefits in younger obese populations, but its specific effects, safety profile, and impact on body composition (e.g., preserving lean mass) in the elderly obese require dedicated investigation. This study aims to address this critical knowledge gap.

This is a single-center, prospective, controlled, randomized, and open-label study designed to investigate the effect of adding <b>semaglutide</b> to a standard-of-care weight loss intervention. The intervention includes personalized lifestyle and exercise guidance for elderly obese subjects. The primary endpoints are changes in body weight and body composition, which will be rigorously assessed using DEXA scans. The abstract specifies a controlled and randomized design, implying a comparison against standard care alone, but does not detail the specific number of participants (n), the exact dose, route, frequency, or duration of semaglutide administration.